Aging & Elder Health Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging & Elder Health Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Glades Pharmaceuticals, LLC
Griseofulvin antifungal agent launched
April 10th, 2005
Glades Pharmaceuticals, LLC, a wholly owned subsidiary of Stiefel Laboratories, Inc., an independent pharmaceutical company specializing in dermatology, announced it has received U.S. Food and Drug Administration (FDA) approval for Griseofulvin Oral Suspension, USP 125 mg/5 mL. This product is the first and only AB-rated generic version of Grifulvin V. Griseofulvin Oral Suspension, USP acts systemically to inhibit the growth of Trichophyton, Microsporum, and Epidermophyton genera of fungi. Major indications for Griseofulvin Oral Suspension, USP are Tinea capitis (ringworm of the scalp), Tinea corporis (ringworm of...
Source: Aging & Elder Health Week (2005-04-10)
|
